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Abstract
Theimpact of minordrug-resistant variants of the type1 immunodeficiencyvirus(HIV-1) onthe failure of antiretroviraltherapy
remains unclear. We have evaluated the importance of detecting minor populations of viruses resistant to non-nucleoside
reverse-transcriptase inhibitors (NNRTI) during intermittent antiretroviral therapy, a high-risk context for the emergence of
drug-resistant HIV-1. We carried out a longitudinal study on plasma samples taken from 21 patients given efavirenz and
enrolled in the intermittent arm of the ANRS 106 trial. Allele-specific real-time PCR was used to detect and quantify minor
K103N mutants during off-therapy periods. The concordance with ultra-deep pyrosequencing was assessed for 11 patients.
The pharmacokinetics of efavirenz was assayed to determine whether its variability could influence the emergence of K103N
mutants. Allele-specific real-time PCR detected K103N mutants in 15 of the 19 analyzable patients at the end of an off-therapy
period while direct sequencing detected mutants in only 6 patients. The frequency of K103N mutants was ,0.1% in 7 patients
by allele-specific real-time PCR without further selection, and .0.1% in 8. It was 0.1%–10% in 6 of these 8 patients. The
mutated virus populations of 4 of these 6 patients underwent further selection and treatment failed for 2 of them. The K103N
mutant frequency was .10% in the remaining 2, treatment failed for one. The copy numbers of K103N variants quantified by
allele-specific real-time PCR and ultra-deep pyrosequencing agreed closely (r=0.89 P,0.0001). The half-life of efavirenz was
higher (50.5 hours) in the 8 patients in whom K103N emerged (.0.1%) than in the 11 patients in whom it did not (32 hours)
(P=0.04). Thus ultrasensitive methods could prove more useful than direct sequencing for predicting treatment failure in
some patients. However the presence of minor NNRTI-resistant viruses need not always result in virological escape.
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Introduction
The remarkable benefits of combinations of antiretroviral drugs
in controlling human immunodeficiency virus type 1 (HIV-1)
infections can be compromised by the development of drug
resistance. Non-nucleoside reverse transcriptase inhibitors
(NNRTIs), notably efavirenz, are highly effective and are
commonly used to treat HIV-1 infections [1–3]. However, HIV-
1 has a low genetic barrier to the development of resistance
towards these compounds as a result of virus mutations at specific
positions on the pol gene. The lysine (K) to asparagine (N)
mutation at codon 103 (K103N) in particular confers great
resistance to efavirenz [4,5].
Direct sequencing is currently used for routine HIV-1
genotyping [6], but it only detects mutated viruses if they account
for more than 10 to 20% of the virus population [7]. Increased
rates of virological failure to NNRTI-containing regimen have
been observed in subjects previously exposed to NNRTIs, despite
the fact that no mutations associated with resistance to these
compounds was detected by direct sequencing of the HIV-1 pol
gene at baseline [8,9]. These observations suggest that pre-existent
but undetected minor populations of mutated viruses contributed
to the subsequent treatment failure. More sensitive methods for
detecting minor mutated viruses have been developed, the main
ones are allele-specific real-time PCR and ultra-deep pyrose-
quencing [7,10–20]. Such ultrasensitive methods have retrospec-
tively detected minor populations of mutated viruses in baseline
virus populations in cases of virological escape to NNRTIs
[16,18,21–23]. However, these methods are not currently used in
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but also because their clinical benefit remains to be demonstrated
in prospective studies. In addition the agreement between allele-
specific real-time PCR and ultra-deep pyrosequencing for
quantifying minor mutated viruses has not been assessed. Lastly,
the clinically relevant threshold above which minor mutated
viruses might significantly influence the virological response to
antiretroviral therapy remains unclear.
Various strategies of intermittent antiretroviral therapy have
been investigated during the past decade as ways of reducing drug-
induced toxicity and costs and improving long-term adherence
[24–27]. However, repeated treatment interruptions have raised
questions about the possible emergence of resistant viruses [28–
30]. A particular concern is the risk of the virus becoming resistant
to efavirenz because of the low genetic barrier of HIV-1 to the
development of resistance towards this drug and its long half-life
that could result in efavirenz monotherapy if the other drugs of the
regimen are more rapidly cleared after treatment interruption.
The randomized multicenter open-label ANRS 106 Window
trial compared a fixed intermittent strategy of six cycles of
alternating 8 weeks off-therapy and 8 weeks on-therapy with
continuous therapy over a 96-week period [24]. NNRTI-
associated resistance mutations, as assessed by direct sequencing,
increased over time in the plasma of patients in the intermittent
arm receiving NNRTIs [31]. We have now evaluated the
performances of allele-specific real-time PCR and ultra-deep
pyrosequencing for detecting the emergence of minor virus
populations harboring the K103N mutation in patients in the
intermittent arm receiving efavirenz. We also investigated whether
the pharmacokinetics variability of efavirenz influenced the
emergence of K103N mutants and analyzed the impact of
emergent K103N mutants on the subsequent virological response
to combined antiretroviral therapy (cART).
Methods
Ethics statement
The protocol was approved by the ethics committee of Toulouse
University Purpan Hospital and by the Agence Nationale de
Recherches sur le SIDA et les He ´patites Virales (ANRS). All
patients gave written informed consent. The study is registered at
clinicaltrials.gov, no. NCT 00122551.
Study subjects
The 21 HIV-1infected patientshad prospectivelybeen included in
a substudy of the ANRS 106 trial, on the basis of (i) being in the
intermittent arm ; (ii) receiving efavirenz ; (iii) providing informed
consent for additionnal blood samples required for the efavirenz
pharmacokinetics study. They all had a nadir pre-treatment CD4
+T-
cell count of $100 cells/mL, and a CD4
+ T-cell count of $450 cells/
mL at screening, and their HIV-1 RNA had been ,200 copies/mL
for at least the previous 6 months. They underwent a total of 6 cycles
starting with 8 weeks off-therapy, followed by 8 weeks on-therapy.
Efavirenz was stopped 7 days before the other drugs at the start of
each off-therapy period [24]. Virological success under intermittent
antiretroviral therapy was defined as a plasma virus load of #400
copies/mL at week 96, at the end of the 6
th on-therapy period.
Sample processing and RNA extraction
Virus particles were pelleted from 1 ml of plasma by
ultracentrifugation at 23,500 g for 1 h at 4uC before RNA
extraction using the QIAamp viral RNA extraction kit (Qiagen).
All the RNA extracted was then used in RT-PCR amplifications.
Direct sequencing
Genotypic resistance tests were performed on plasma at the end
of each off-therapy period. A first RT-PCR amplification step was
performed with the QIAgen one step RT-PCR kit (Qiangen) and
the following primers: forward 59-ATTTTCCCATTAGTCC-
TATT-39 and reverse 59-ATGTCATTGACAGTCCAGCT-39.
A nested PCR was then performed with the Expand High Fidelity
Plus PCR System (Roche Diagnostics) and the following primers:
forward 59- CCAAAAGTTAAACAATGGCCATTGACAGA-39
and reverse 59- AGTTCATAACCCATCCAAAG -39. Bulk PCR
products were sequenced in both directions by the dideoxy chain
termination method (BigDye Terminator; Applied Biosystems) on
an ABI 3130 DNA sequencer as previously described [31].
Ultra-deep pyrosequencing
The first RT-PCR amplification step was common for direct
sequencing and ultra-deep pyrosequencing. The mean virus load
of the samples assesed was 67,792 copies/mL (range 1,200–
454,000 copies/mL). A 469-nucleotide long fragment encompass-
ing the reverse-transcriptase gene between codons 88 and 243 was
then generated by nested PCR from the RT-PCR products. The
nested PCR was performed with the Expand High Fidelity Plus
PCR System (Roche Diagnostics). The deep sequencing primers
are composed of fusion primers (59 part) to fuse to the emulsion
PCR beads, a four-base ‘‘key’’ sequence to define the DNA
library, multiplex identifiers to enable for the identification of
samples after pooling and sequencing, and a target-specific
sequence (forward 59-GGAAGTTCAATTAGGAATACCACA-
39 and reverse 59- TATAGGCTGTACTGTCCATTTGTC-39).
The amplified PCR products were purified using Agencourt
Ampure PCR Purification beads (Beckman Coulter) and quanti-
fied with the Quant-iT Picogreen dsDNA Assay Kit (Invitrogen)
on a LightCycler 480 (Roche). Pooled PCR products were clonally
amplified on capture beads in water-in-oil emulsion micro-
reactors. A total of 500,000 enriched-DNA beads were deposited
in the wells of a full GS Junior Titanium PicoTiterPlate device and
pyrosequenced in both forward and reverse directions. The 200
nucleotide flow cycles allow to sequence a 500 bp fragment in a
10-hour sequencing run as about 2.5 nucleotides would be
incorporated per nucleotide flow cycle. The sequence reads were
quantified with GS Amplicon Variant Analyzer (AVA) software
Version 2.5p1 (Roche). The AVA software assigns each read to the
proper amplicon and sample using multiplex identifiers. The
sequence reads were aligned with the HXB2 consensus sequence.
We assessed the frequency of errors resulting from PCR
amplification and GS Junior pyrosequencing at codon 103 by
analyzing the pyrosequencing data from a panel of 9 plasmid
clones previously sequenced by the Sanger method (5 of 9 clones
had ‘‘AAA’’ at position 103 encoding ‘‘K’’, one had ‘‘AAG’’, also
encoding ‘‘K’’, and 3 had ‘‘AAC’’ encoding ‘‘N’’). The mean error
rate of pyrosequencing at codon 103 was 0.0047 [CI99, 0.00085–
0.00856]. The upper confidence limit of the error rate was used to
calculate the sensitivity of pyrosequencing for a given number of
reads. At least 2500 reads reliably detects minor K103N mutants
when they accounted for over 1.5% of the quasispecies. Fig. 1
shows the detection threshold as a function of the read number.
Allele-specific real-time PCR
A first round of amplification was performed with a forward
primer (59-ACATCCCGCAGGGTTAAAAAAGAA-39) located
immediately upstream of the third nucleotide of the 103
th codon of
the reverse transcriptase gene, and a reverse primer (59-
AGTTCATAACCCATCCAAAG-39) using the QIAgen one step
RT-PCR kit (Qiagen) with the following conditions : 30 min of
Impact of Minor K103N HIV-1 Variants
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21655reverse transcription at 50uC; 15 min of inactivation at 94uC;
30 sec at 94uC, 30 sec at 55uC, and 1 min at 72uC for 40 cycles.
The RNA input was adjusted for 50,000 HIV-1 copies per
reaction. With this input, the first amplification was linear for 40
cycles (data not shown). This first round of amplification corrected
for potential polymorphims of the targeted sequence to ensure that
only the third nucleotide of the 103
th codon was discriminant in
the nested allele-specific amplification. Then 4 allele-specific real-
time PCR real-time amplifications were performed in parallel to
quantify the AAA and AAG wild-type codons (encoding «K»), and
the AAC and AAT mutated codons (encoding «N») using the 4
specific forward primers 59-CCGCAGGGTTAAAAAAGAIA/G/
C/T-39 and the reverse primer 59-GGTTCTTTCTGATGTTT-
TTTGTCTGG-39 and a Taqman probe 59-famATGTGGGT-
GATGCATATTTTTCAGTTCtamra-39 on a LightCycler
(Roche) with the following conditions :10 min at 95uC; 15 sec at
95uC, 1 min at 62uC for 50 cycles. Each quantification was
performed using a standard curve obtained by serial dilutions of a
plasmid containing one of the targeted AAA, AAG, AAC, and
AAT sequences cloned into a pCR4-TOPO vector (Invitrogen).
The specificity of each amplification was assessed by amplifying
equal quantities of the targeted and non-targeted sequences. The
amplification specific for the AAC mutated sequence resulted in
2
20 and 2
16 more efficient amplifications of the targeted AAC
sequence than the non-targeted AAA and AAG wild-type
sequences. The amplification specific for the AAT mutated
sequence resulted in 2
29 and 2
21 more efficient amplifications of
the targeted AAT sequence than the non-targeted AAA and AAG
wild-type sequences. The input for quantifying the mutated
sequences was adjusted for 5,000 copies per reaction based on the
quantification of wild-type sequences. The AAC and AAT
amplifications were specific enough to extinguish the wild-type
sequences in the amplification. The sensitivity of our allele-specific
PCR assay to detect K103N mutants was assessed on mixtures of
wild-type and K103N mutants. Our assay detects K103N mutants
down to a frequency of 0.01%. This 0.01% threshold of detection
was thus used in the study. A plot of the measured values versus
the input was linear across a wide range of K103N mutants
frequencies (Fig. 2A). Reciprocal validation of allele-specific PCR
and ultra-deep pyrosequencing was also performed by quantifying
in parallel mixtures of wild-type and K103N mutants with known
proportions of K103N by the two methods (Fig. 2B and 2C).
Quantitative determination of efavirenz in the plasma
We used high-performance liquid chromatography (HPLC)
with UV detection to determine efavirenz concentrations in the
plasma 1, 3, 7, and 10 days after interrupting efavirenz therapy to
assess interindividual variations. Half-lives were calculated from
the slope of concentrations decline versus time.
Statistical analysis
Quantitative variables were compared using the Wilcoxon rank
sum test. Correlations between quantitative variables were
estimated by calculating Spearman’s rank correlation coefficient.
Poisson distribution was used to distinguish authentic variants
from artefactual sequences resulting from errors arising during
PCR amplification and ultra-deep pyrosequencing. Only those
variants whose frequency of occurrence yielded a P value of
,0.001 according to the Poisson model were considered
authentic. Statistical analyses were performed with Stata SE 9.2.
Results
Patient characteristics at baseline
The 21 patients (15 men, 6 women) had a median age of 38.6
years-old (range, 23.8–59.9), a median CD4
+ T-lymphocyte count
of 648 cells/mL (range, 435–1151), and all had plasma virus load
,200 copies/mL. They were all receiving a backbone of
nucleoside reverse transcriptase inhibitors associated with efavir-
enz, plus a protease inhibitor for 3 of them.
Detection of K103N mutations by allele-specific real-time
PCR
The allele-specific real-time PCR to detect K103N mutations
could not be performed in 2 patients (harboring wild-type viruses
by direct sequencing) because of amplification failure. K103N
mutants were detected at the end of an off-therapy period in 15 of
the 19 analyzable patients by allele-specific real-time PCR, but in
only 6 of these 19 patients by direct sequencing. The frequency of
K103N mutants in the quasispecies remained below 0.1%
Figure 1. Detection threshold of ultra-deep pyrosequencing for detecting minor K103N variants in function of the read number.
The mean error rate of pyrosequencing at codon 103 was 0.0047 [CI99, 0.00085–0.00856]. The upper confidence limit of the error rate was used to
calculate the sensitivity of pyrosequencing for a given number of reads. Poisson distribution was used to distinguish authentic variants from
artefactual sequences resulting from errors arising during PCR amplification and ultra-deep pyrosequencing. Only those variants whose frequency of
occurrence yielded a P value of ,0.001 according to the Poisson model were considered authentic.
doi:10.1371/journal.pone.0021655.g001
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selection. The initial frequency of K103N mutants was 0.1–1% in
2 of the 15 patients, and further increased to become predominant
in one of them. The initial frequency of K103N mutants was 1–
10% in 4 of the 15 patients, with further selection in 3 of them.
Lastly, the initial frequency of K103N mutants was above 10% in
2 of the 15 patients (Table 1).
Allele-specific real-time PCR detected minor K103N mutants in
9 more patients than did direct sequencing; the frequency of
K103N mutants was ,0.1% in 7 of them, and 1% and 2.8% in
the 2 others. The K103N mutants detected by allele-specific real-
time PCR in 6 patients were also detected by direct sequencing
(Table 1). Allele-specific real-time PCR detected the mutants
earlier (week 40) during the selection of drug-resistant viruses than
did direct sequencing (week 56) in 3 of them (patients 13, 15, and
16). The frequencies of K103N mutants were 0.24%, 1.9%, and
5.8% in these 3 patients when they were first detected by allele-
specific real-time PCR at week 40, and they increased to 84.7%,
29.9%, and 11% when detected later by direct sequencing. Allele-
specific real-time PCR and direct sequencing detected K103N
mutants at the same time in the 3 other patients (patients 17, 18,
and 19). The frequencies of K103N mutants in these latter 3
patients were 5% (at week 8), 99.6% (at week 8), and 24.9% (at
week 72) when they were detected by both methods.
The number of K103N copies per mL of plasma was calculated
by multiplying the proportion of K103N mutants by the plasma
virus load. The absolute numbers of drug-resistant copies in
patients with low frequencies of K103N mutants who experienced
subsequent selection of their mutated virus populations were 1.54
log10 (0.24%, patient 13), 3.65 log10 (1.9%, patient 15), 3.97 log10
(5.8%, patient 16), and 3.04 log10 (5% ; patient 17) per mL plasma
when first detected by allele-specific real-time PCR (Table 2).
Detection of K103N mutations by ultra-deep
pyrosequencing
The presence of the K103N mutation was assessed by ultra-
deep pyrosequencing in 11 of the patients for whom enough
plasma samples were available. An average of 3592 analyzable
reads was obtained per sample, which enable minor K103N
variants accounting for 1.4% of the quasispecies to be detected
(Fig. 1). Ultra-deep pyrosequencing did not detect the K103N
mutants that were detected by allele-specific real-time PCR at the
same stage in 5 samples (frequencies of 0.03%, 0.05%, 0.1%, 1%,
and 1.7%), but higher frequencies were detected by both methods
with good agreement (Table 2). The frequencies and copy
numbers of K103N mutants quantified in parallel by allele-
specific real-time PCR and ultra-deep pyrosequencing were
strongly correlated (r=0.79 P,0.001, and r=0.89 P,0.0001,
respectively) (Fig. 3A and 3B).
Impact of variations in the pharmacokinetics of efavirenz
on K103N mutation emergence
Efavirenz was stopped 7 days before the other drugs of the
regimen at each off-therapy period to take into account its long
half-life. The median concentration of efavirenz after interruption
was 1962 ng/ml (range, 728–4146) on day 1, 416 ng/ml (range,
95–1390) on day 3, 112 ng/ml (range, ,50–749) at day 7, and
50 ng/ml (range, ,50–631) on day 10. Estimations of the half-life
of efavirenz revealed great inter-individual variations, from 27 to
136 hours. Thus, even stopping efavirenz 7 days before the other
drugs of the regimen could result in efavirenz monotherapy in
some patients. The median efavirenz half-life was 32 hours (CI95
[28.7–75.3]) in patients harboring no or few (,0.1%) K103N
Figure 2. Sensitivity of the allele-specific PCR assay for
detecting minor K103N mutants and reciprocal validation with
ultra-deep pyrosequencing. A. Plot of the measured frequencies of
K103N mutants versus the input template, assessed on four indepen-
dent experiments of mixtures of wild-type and K103N mutants at
various frequencies. The inter-assay variability is shown by error bars
representing the standard deviation. The assay detects K103N mutants
down to a frequency of 0.01% in all experiments. B. Measured
frequencies of K103N mutants on mixtures of wild-type and K103N
mutants with known proportions of K103N. C. Correlation between
measurements by the two methods.
doi:10.1371/journal.pone.0021655.g002
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whom allele-specific real-time PCR detected a significant frequen-
cy (.0.1%) of K103N mutants (n=8) (P=0.04) (Fig. 4).
Influence of emergent K103N mutations on the
subsequent virological response to cART
We analyzed the impact of emergent K103N mutants on the
subsequent virological response to cART in the 15 patients in
whom K103N mutants had been detected by allele-specific real-
time PCR. It had no influence on the virological response to
cART in the 7 patients whose frequency of K103N mutants
remained ,0.1% without further selection. By contrast, the
emergence of K103N mutations in the other 8 patients with
.0.1% K103N mutants resulted in treatment failure in 3 of them;
the remaining 5 maintained a virological response to cART during
on-therapy periods (plasma virus load #400 copies/mL). K103N
mutants were abundant in 2 patients (patients 17 and 19) who
were on stavudine, didanosine, and efavirenz, one from the end of
the first off-therapy period (99.6%) and the other from the end of
the second (85.5%); they experienced treatment failure thereafter.
The third patient (patient 15) who experienced treatment failure
was on stavudine, lamivudine, and efavirenz. The gradual
emergence of K103N mutants was first detected by allele-specific
real-time PCR during the third off-therapy period (1.9% at week
40), and the mutated population was then selected at each cycle
until the virus population was almost totally mutated (91.9%) at
week 88. Treatment failed in this patient after the fifth on-therapy
period. By contrast, treatment failure did not occur in 5 patients
despite the presence of K103N mutants: the frequency of K103N
mutants remained quite low (maximum 1% and 2.8%) in patients
12 and 14, it was high (48.4%) in another (patient 16) who was also
given indinavir in addition to efavirenz and lamivudine, and the
frequencies of K103N mutants were high (24.9%, and 84.7%) in
the remaining 2 patients (patients 13 and 18) who were given only
two nucleoside reverse transcriptase inhibitors plus efavirenz. The
follow-up data available for these 2 patients showed that they still
had an undetectable plasma virus load (,50 copies/mL) 40 weeks
after the end of the trial when they were on continuous therapy
with the same regimen.
Discussion
We have assessed the performances of allele-specific real-time
PCR and ultra-deep pyrosequencing for detecting minor K103N
mutants in patients given efavirenz while on intermittent
antiretroviral therapy. An earlier analysis by direct sequencing
revealed that the proportion of patients in the intermittent arm
given NNRTIs in whose plasma NNRTI-associated resistance
mutations were detected increased over time from 3% at the end
of the first off-therapy period to 27% at the end of the sixth off-
therapy period [31]. We have now retrospectively evaluated two
ultrasensitive methods for detecting K103N mutants in this
context at high risk for the emergence of resistance.
Allele-specific real-time PCR detected K103N mutants in 9
more patients harboring a low frequency of mutated viruses than
did direct sequencing. Allele-specific real-time PCR also provided
earlier detection than direct sequencing during the selection of
drug-resistant viruses. Plasma samples from 11 patients were
assayed by both allele-specific real-time PCR and ultra-deep
pyrosequencing. Ultra-deep pyrosequencing is prone to artefactual
errors. We have measured the sequence error rate at codon 103
resulting from PCR amplification and ultra-deep pyrosequencing
by comparing the GS junior reads to the Sanger sequences of 9
plasmid clones. We used the upper 99% confidence limit of the
Table 1. Longitudinal assessment of K103N mutants frequency by allele-specific PCR during the intermittent off-therapy periods.
Frequency of K103N mutants by allele-specific PCR (%)
Patient w8 w24 w40 w56 w72 w88 Treatment failure
1 0000- - N
2 000- 0- N
3 0 0-0--N
4 - 0000- N
5 0.01 0 0 0.01 0 0.03 N
6 0.03 0.01 0 0.03 - - N
7 0.07 0.05 0.01 - - - N
8 0 0 0.02 0.01 0.03 0.01 N
9 0.01 0.01 0 0.02 - - N
10 0 0.01 - - - - N
11 0 0.01 - - - - N
12 00 . 1 0001N
13 0 0 0.24 84.7* 72.3* - N
14 00002 . 8 - N
15 0 0 1.9 29.9* 61.6* 91.9* Y
16 0 0 5.8 11* - 48.4* N
17 5* 85.5* 48.7* 66.9* - - Y
18 - 0 0 0 24.9* 8.9* N
19 99.6* 99.2* - - - - Y
w, week; Y, yes; N, no; *, K103N mutants also detected by direct sequencing; dashes, samples not available.
doi:10.1371/journal.pone.0021655.t001
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given number of reads and the Poisson distribution to estimate the
number of reads above which K103N mutants found at low
frequencies were authentic rather than artefactual. Only those
variants whose frequency of occurrence yielded a P value of
,0.001 according to the Poisson model were considered
authentic. Our assay on the GS Junior can detect K103N minor
variants that account for 1.5% of total virus if the number of reads
is above 2500. But ultra-deep pyrosequencing was not as sensitive
as allele-specific real-time PCR for detecting K103N mutants at
very low frequency. However, unlike allele-specific real-time PCR,
ultra-deep pyrosequencing can determine whether HIV-1 drug-
resistance mutations are linked on a given sequence or are borne
separately by different virus clones. Globally, the results obtained
Table 2. K103N mutants in 11 patients quantified by allele-specific real-time PCR and ultra-deep pyrosequencing.
K103N quantified by allele-specific PCR K103N quantified by pyrosequencing
Patient Stage
Input template
(log10 HIV-1
copies/ml) AAC codon AAT codon AAC codon AAT codon
1 w40 4.76 0 - 0 0
2 w72 5.45 0 0 0 0
5 w72 3.70 0 - 0 0
8 w72 5.00 0.03% (1.42) - 0 0
12 w8 3.91 0 - 0 0
w24 3.60 0.1% (0.60) - 0 0
w40 3.59 0 - 0 0
w56 3.83 0 - - -
w72 4.01 0 - - -
w88 3.81 1% (1.81) 0 0 0
13 w8 5.18 0 - 0 0
w24 4.46 0 - 0 0
w40 4.16 0.24% (1.54) - 3.7% (2.73) 0
w56 4.04 84.7% (3.97) - 38.7% (3.63) 0
w72 3.87 72.3% (3.73) 0 33.2% (3.39) 0
14 w8 4.97 0 - 0 0
w24 4.89 0 - 0 0
w40 4.40 0 - 0 0
w56 4.73 0 - 0 0
w72 4.16 2.8% (2.61) 0 4.8% (2.84) 0
15 w8 5.65 0 0 - -
w40 5.37 1.9% (3.65) 0 2.9% (3.83) 0
w56 4.94 29.9% (4.42) 0 55.1% (4.69) 0
w72 5.16 61.6% (4.94) 0.05% (1.85) 89.3% (5.11) 0
w88 5.23 90.2% (5.19) 1.7% (3.46) 79.4% (5.13) 0
16 w8 5.66 0 0 0 0
w40 5.20 5.8% (3.97) 0 5.7% (3.96) 0
w56 5.01 11% (4.05) 0 17.9% (4.26) 0
w88 4.98 47.8% (4.66) 0.6% (2.76) - -
17 w8 4.34 5% (3.04) - 19.8% (3.64) 0
w24 3.08 85.5% (3.01) - 84.5% (3.01) 0
w40 3.11 48.7% (2.80) - 80.6% (3.02) 0
w56 4.65 66.9% (4.47) 0 75.4% (4.52) 0
18 w24 3.71 0 - 0 0
w40 3.65 0 0 0 0
w56 3.84 0 0 0 0
w72 3.68 0 24.9% (3.08) 0 10.2% (2.69)
w88 3.69 0 8.9% (2.64) 0 43.1% (3.33)
The frequencies of K103N mutants are shown with corresponding absolute numbers of K103N log10 copies per mL of plasma in brackets.
w, week; AAC and AAT codons encode the asparagine « N » at position 103; dashes, samples not available.
doi:10.1371/journal.pone.0021655.t002
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correlated, providing reciprocal validation of each method.
We assayed the pharmacokinetics of efavirenz to determine
whether its variability could influence the emergence of the
K103N mutation. We found that its half-life varied greatly
between individuals, from 27 to 136 hours. Thus, stopping
efavirenz even 7 days before the other drugs of the regimen could
result in efavirenz monotherapy in some patients, a situation in
which the risk of NNRTIs resistance emerging is high. This may
have occurred as the half-life of efavirenz was significantly higher
in the 8 patients in whom K103N emerged than in the 11 patients
in whom it did not. However, the small sample size precludes
higher levels of statistical significance required for a definite
conclusion.
The impact of emergent K103N mutations on the subsequent
virological response to cART in the 8 patients harboring .0.1%
of the K103N mutated viruses varied. It resulted in treatment
failure in 3 patients while 5 paradoxically maintained a virological
response to antiretroviral therapy during each on-therapy period.
However, 2 of the patients who responded to cART had only a
few K103N mutants. A third patient with a high frequency of
K103N mutants was given a protease inhibitor in addition to
efavirenz, and this could have contributed to the virological
response. The last 2 patients had high frequencies of K103N
mutants but paradoxically maintained a virological response on
efavirenz-based regimen during the intermittent therapy scheme,
and on continuous therapy with the same regimen upon
completion of the study. Genotypic methods for inferring HIV-1
resistance rely on the presence of known mutations at specific
positions of the HIV-1 genome, but cannot assess the impact of
changes in the replicative fitness or infectiousness of some viruses
[32]. The K103N mutants found in the patients who paradoxically
responded to cART might have had altered replicative fitness.
This may have occurred as we have previously shown that patients
with drug resistant viruses had lower virus rebounds and decreases
in CD4
+ T cells during the period of intermittent therapy than did
patients with wild-type viruses [31].
The clinical relevancy of detecting minor populations of
mutated viruses remains open to debate. There is growing
evidence that the presence of minor mutated viruses at baseline
has a deleterious impact on the subsequent response to cART
[8,11,16,17,21–23,33]. However, others found that low frequen-
cies of minor drug-resistant viruses had no impact [34,35,36].
Thus, the threshold above which minor mutated viruses might
significantly influence the virological response to antiretroviral
therapy remains unclear. Spontaneous mutants resulting from
random polymorphisms could occur in 0.03%60.03% of the virus
population, in the absence of antiretroviral therapy [37,38]. Thus,
the ,0.1% of mutated viruses could be due to spontaneous
polymorphisms rather than drug-resistant viruses emerging under
drug selective pressure. The possibility of false detection of drug-
resistant mutants by ultrasensitive methods cannot also be
excluded. The 7 patients harboring ,0.1% K103N mutants, as
detected by allele-specific real-time PCR, experienced no further
selection of their mutated viruses, or treatment failure. By contrast,
the mutated virus populations of 4 of the 6 patients harboring 0.1–
10% K103N mutants underwent further selection and treatment
Figure 3. Correlation between K103N mutants quantified by allele-specific real-time PCR and ultra-deep pyrosequencing. A.
Frequencies of K103N mutants. B. Number of K103N mutant copies The correlation was estimated by calculating Spearman’s rank correlation
coefficient for 16 samples successfully quantified by both methods for the AAC and/or AAT mutated codons.
doi:10.1371/journal.pone.0021655.g003
Figure 4. Higher efavirenz half-life in patients in whom K103N
emerged than in whom it did not. The Wilcoxon rank sum test was
used for the comparison.
doi:10.1371/journal.pone.0021655.g004
Impact of Minor K103N HIV-1 Variants
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21655failed for 2 of these patients. The threshold above which minor
K103N mutants could lead to virological escape seemed to be 0.1–
1%. A previous report indicated that patients with more than
2,000 (3.3 log10) copies/mL plasma of drug-resistant viruses
experienced further selection of this population [39]. We found
that 3 of the 4 patients in whom drug-resistant viruses
subsequently emerged had over 3 log10 copies/mL K103N
mutants when first detected by allele-specific real-time PCR.
The fourth had under 3 log10 copies/mL of K103N mutants but
nevertheless underwent further selection of the mutated virus
population. A recent pooled analysis found that low-frequency
NNRTI resistance mutations confer a greater than 2-fold risk of
virologic failure in treatment-naive individuals initiating a first-line
NNRTI-containing cART regimen. A dose-dependent association
of drug-resistant minority variants with increased risk of virologic
failure was observed. Absolute numbers of drug-resistant minority
variants over 1 log10 copies/mL plasma appear to be associated
with a statistically significant higher risk of virological failure [40].
In conclusion, we have found that allele-specific real-time PCR
and ultra-deep pyrosequencing are more sensitive than direct
sequencing for detecting K103N mutants in the particular setting
of intermittent antiretroviral therapy, with an excellent correlation
between both mehods for quantifying the mutated viruses. These
ultrasensitive methods could be more useful than direct sequencing
for predicting treatment failure in some patients. But the presence
of minor resistant viruses need not always lead to subsequent
virological escape. Large prospective studies are now needed to
demonstrate the clinical relevance of detecting minor resistant
virus populations for adapting antiretroviral therapy.
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